• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫检查点调节剂 LAG-3 和 TIM-3 在经典型霍奇金淋巴瘤中的表达。

Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.

机构信息

Department of Hematology, Gustave Roussy, Villejuif, France.

Department of Pathology, Gustave Roussy, Villejuif, France.

出版信息

Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):257-266.e3. doi: 10.1016/j.clml.2020.11.009. Epub 2020 Nov 12.

DOI:10.1016/j.clml.2020.11.009
PMID:33277223
Abstract

INTRODUCTION

The role of the programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) axis is well established in classical Hodgkin lymphoma (HL), where PD-1 blockade demonstrated spectacular efficacy in relapsed/refractory disease. However, little is known about the frequency and cellular distribution of other immune checkpoints in HL samples.

PATIENTS AND METHODS

Using immunohistochemistry, we investigated, along with PD-L1 and PD-1, the expression of lymphocyte-activation gene 3 (LAG-3) and T-cell immunoglobulin and mucin-domain containing 3 (TIM-3) in 57 biopsy samples of patients with classical HL.

RESULTS

Hodgkin and Reed/Sternberg (HRS) cells were strongly positive for PD-L1 in nearly all cases. HRS cells were TIM-3 positive in 36% of samples, whereas LAG-3 was rarely expressed (5.2%). In the microenvironment, PD-1, LAG-3, and TIM-3 were expressed by ≥ 5% of cells in 65%, 98%, and 96% of cases, respectively. T-cell rosettes surrounding HRS cells consisted of CD4 FoxP3- helper T cells expressing both PD-1 and LAG-3, with a variable expression of TIM-3.

CONCLUSION

This study demonstrates for the first time that LAG-3 and TIM-3 are nearly always expressed in the microenvironment of classical HL. This may constitute the basis for targeting LAG-3 or TIM-3 in combination with anti-PD-1 antibodies in the treatment of relapsed/refractory HL.

摘要

简介

程序性细胞死亡 1(PD-1)/程序性死亡配体 1(PD-L1)轴在经典霍奇金淋巴瘤(HL)中的作用已得到充分证实,在复发/难治性疾病中,PD-1 阻断显示出了显著的疗效。然而,对于 HL 样本中其他免疫检查点的频率和细胞分布知之甚少。

患者和方法

我们使用免疫组织化学法,在 57 例经典 HL 患者的活检样本中,除了 PD-L1 和 PD-1 外,还检测了淋巴细胞激活基因 3(LAG-3)和 T 细胞免疫球蛋白和粘蛋白结构域 3(TIM-3)的表达情况。

结果

几乎所有病例的霍奇金和里斯/斯特恩伯格(HRS)细胞均强烈表达 PD-L1。36%的样本中 HRS 细胞 TIM-3 阳性,而 LAG-3 则很少表达(5.2%)。在微环境中,PD-1、LAG-3 和 TIM-3 的表达在 65%、98%和 96%的病例中分别有≥5%的细胞表达。围绕 HRS 细胞的 T 细胞玫瑰花结由 CD4 FoxP3-辅助 T 细胞组成,这些细胞表达 PD-1 和 LAG-3,TIM-3 的表达具有可变性。

结论

本研究首次证明 LAG-3 和 TIM-3 在经典 HL 的微环境中几乎总是表达。这可能为在复发/难治性 HL 的治疗中联合使用抗 PD-1 抗体靶向 LAG-3 或 TIM-3 提供了依据。

相似文献

1
Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.免疫检查点调节剂 LAG-3 和 TIM-3 在经典型霍奇金淋巴瘤中的表达。
Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):257-266.e3. doi: 10.1016/j.clml.2020.11.009. Epub 2020 Nov 12.
2
High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.PD-1 抑制剂在复发/难治性经典型霍奇金淋巴瘤中 PD-L1 抑制剂初始失败后的高疗效。
BMC Cancer. 2022 Jan 3;22(1):9. doi: 10.1186/s12885-021-09028-4.
3
DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.在人原发性乳腺癌中,PD-1、CTLA-4、TIM-3、LAG-3、TIGIT 和 PD-L1 基因启动子区域的 DNA 甲基化和抑制性 H3K9 和 H3K27 三甲基化。
Clin Epigenetics. 2018 Jun 15;10:78. doi: 10.1186/s13148-018-0512-1. eCollection 2018.
4
Where does PD-1 blockade fit in HL therapy?PD-1 阻断疗法在 HL 治疗中的地位如何?
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):213-220. doi: 10.1182/asheducation-2018.1.213.
5
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.拓扑分析揭示了霍奇金淋巴瘤中里德-施特恩伯格细胞的一种与程序性死亡配体1相关的微环境生态位。
Blood. 2017 Nov 30;130(22):2420-2430. doi: 10.1182/blood-2017-03-770719. Epub 2017 Sep 11.
6
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.主要组织相容性复合体 II 类和程序性死亡配体 1 表达预测经典霍奇金淋巴瘤接受程序性死亡 1 阻断后的结局。
J Clin Oncol. 2018 Apr 1;36(10):942-950. doi: 10.1200/JCO.2017.77.3994. Epub 2018 Feb 2.
7
Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients.尼妥珠单抗治疗期间 TIM-3、LAG-3、IDO、PD-L1 和 CTLA-4 的表达改变与口腔鳞状细胞癌患者的反应和预后相关。
J Oral Pathol Med. 2019 Sep;48(8):669-676. doi: 10.1111/jop.12883. Epub 2019 Jun 9.
8
Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.免疫共抑制受体 PD-1、CTLA-4、TIM-3、LAG-3 和 TIGIT 在甲状腺髓样癌中的表达:一项大样本队列研究。
J Clin Endocrinol Metab. 2021 Jan 1;106(1):120-132. doi: 10.1210/clinem/dgaa701.
9
Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants.PD-1、PD-L1 和 TIM-3 阻断改变了人乳腺癌外植体转录组中独特的免疫和癌症相关信号通路。
Genes (Basel). 2020 Jun 25;11(6):703. doi: 10.3390/genes11060703.
10
Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.免疫组织化学评估 PD-L1 的诊断效用:抗 PD-L1 抗体(SP142)在具有肿瘤和非恶性霍奇金-里德-斯特恩伯格(HRS)样细胞的淋巴增生性疾病中的初步分析。
Histopathology. 2018 Jun;72(7):1156-1163. doi: 10.1111/his.13475. Epub 2018 Mar 9.

引用本文的文献

1
Advances in strategies to improve the immunotherapeutic efficacy of chimeric antigen receptor-T cell therapy for lymphoma.提高嵌合抗原受体T细胞疗法治疗淋巴瘤免疫治疗效果的策略进展
Cancer Biol Med. 2025 Apr 15;22(4):301-21. doi: 10.20892/j.issn.2095-3941.2024.0538.
2
Microenvironmental Traits of Classical Hodgkin's Lymphoma in Adolescents and Their Prognostic Impact.青少年经典型霍奇金淋巴瘤的微环境特征及其预后影响
Cancers (Basel). 2024 Dec 18;16(24):4210. doi: 10.3390/cancers16244210.
3
Immune checkpoints and ncRNAs: pioneering immunotherapy approaches for hematological malignancies.
免疫检查点与非编码RNA:血液系统恶性肿瘤的开创性免疫治疗方法
Cancer Cell Int. 2024 Dec 19;24(1):410. doi: 10.1186/s12935-024-03596-8.
4
Immune checkpoint inhibitors targeting PD-1/PD-L1 in the treatment of human lymphomas.靶向程序性死亡受体-1/程序性死亡配体-1的免疫检查点抑制剂在人类淋巴瘤治疗中的应用
Front Oncol. 2024 Jul 18;14:1420920. doi: 10.3389/fonc.2024.1420920. eCollection 2024.
5
Cross-domain information fusion for enhanced cell population delineation in single-cell spatial-omics data.用于增强单细胞空间组学数据中细胞群体描绘的跨域信息融合
bioRxiv. 2024 May 14:2024.05.12.593710. doi: 10.1101/2024.05.12.593710.
6
Synergistic combination therapy using cowpea mosaic virus intratumoral immunotherapy and Lag-3 checkpoint blockade.利用豇豆花叶病毒瘤内免疫治疗和 Lag-3 检查点阻断的协同联合治疗。
Cancer Immunol Immunother. 2024 Feb 13;73(3):51. doi: 10.1007/s00262-024-03636-2.
7
Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas.淋巴瘤联合治疗中的临床PD-1/PD-L1阻断疗法
Cancers (Basel). 2023 Nov 14;15(22):5399. doi: 10.3390/cancers15225399.
8
Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics.免疫检查点靶向抗体为联合癌症治疗带来希望。
Clin Exp Med. 2023 Dec;23(8):4297-4322. doi: 10.1007/s10238-023-01201-2. Epub 2023 Oct 7.
9
Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy.免疫治疗时代复发性/难治性经典型霍奇金淋巴瘤的治疗优化
Cancers (Basel). 2023 Sep 11;15(18):4509. doi: 10.3390/cancers15184509.
10
DNA-barcoded signal amplification for imaging mass cytometry enables sensitive and highly multiplexed tissue imaging.DNA 条码信号放大用于成像质谱流式细胞术,实现了灵敏和高多重化的组织成像。
Nat Methods. 2023 Sep;20(9):1304-1309. doi: 10.1038/s41592-023-01976-y. Epub 2023 Aug 31.